Tyrosine kinase inhibitorFDA-approvedFirst-line
Brafiib
Generic name: dabrafenib
How it works
Blocks the BRAF V600E mutation, a genetic abnormality that can drive cancer growth. By blocking this mutation, dabrafenib can slow or stop cancer growth.
Cancer types
Melanoma— BRAF V600E-positive
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with a median progression-free survival of approximately 9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Dabrafenib and Trametinib Before and After Surgery for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Treating Advanced Melanoma with Combination Therapies | Melanoma | phase-3 | — | Source → |
| Reduced-Dose Dabrafenib-Trametinib for Lung Cancer in Very Elderly Patient | Lung Cancer | observational | — | Source → |
| New Methods for Detecting Cancer Drug Dabrafenib | Lung Cancer | lab-study | — | Source → |
| Melanoma Drug Exposure Linked to Survival | Melanoma | observational | Median overall survival was significantly longer in patients with trametinib C ≥ 15.6 ng/mL (22.8 vs. 12.6 months, P = 0.003) | Source → |
| Combination Therapy for Metastatic Melanoma Shows Promise | Melanoma | observational | The patient experienced complete remission for 19 months. | Source → |
| New way to deliver cancer drugs to melanoma cells | Melanoma | lab-study | Both DAB- and VEM-loaded NMs elicited enhanced response with respect to free drug treatments in 4 different melanoma cell lines. | Source → |
| Melanoma Treatment Comparison Study | Melanoma | phase-3 | The 2-year overall survival for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1), and arm B 51.5% (95% CI, 41.7 to 60.4). | Source → |
| Dabrafenib and Trametinib Combination Shows Promise in Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 17.5 months and the median overall survival was 25.5 months. | Source → |
| Pembrolizumab and other drugs improve cancer outcomes in melanoma patients | Melanoma | phase-2 | Median progression-free survival was 16.9 months with the combination of pembrolizumab, dabrafenib, and trametinib, compared to 10.7 months with dabrafenib and trametinib alone. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.